Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116961342 | 11696134 | 2 | F | 20140820 | 20160822 | 20151104 | 20160829 | EXP | US-JNJFOC-20151100062 | JANSSEN | 65.76 | YR | A | F | Y | 0.00000 | 20160829 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116961342 | 11696134 | 1 | PS | INVOKANA | CANAGLIFLOZIN | 1 | Oral | BEFORE BREAKFAST | Y | U | 204042 | 300 | MG | TABLET | |||||
| 116961342 | 11696134 | 2 | SS | GLUCOPHAGE | METFORMIN HYDROCHLORIDE | 1 | Oral | Y | 0 | 500 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116961342 | 11696134 | 1 | Type 2 diabetes mellitus |
| 116961342 | 11696134 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116961342 | 11696134 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116961342 | 11696134 | Diabetic ketoacidosis | |
| 116961342 | 11696134 | Myocardial infarction | |
| 116961342 | 11696134 | Renal injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 116961342 | 11696134 | 1 | 201408 | 0 | ||
| 116961342 | 11696134 | 2 | 201408 | 0 |